Asper Biotech has updated its Ashkenazi Jewish Diseases Test to include mutations in the BRCA1, BRCA2, and LCA5 genes that are common in the Ashkenazi Jewish population. Asper's test now detects up to 112 variants in 27 genes.
Asper Biotech recently introduced a number of new test panels targeted to mitochondrial diseases.
Asper Biotech recently launched a new carrier test to detect the most common mutations associated with autosomal recessive disorders that are overrepresented in the Hutterite population.
From its office in Tartu, Estonia, Asper Biotech continues to introduce new microarray-based tests related to reproductive health, oncology, and opthamalogy.
Asper Biotech recently launched a test for Leber hereditary optic neuropathy, or LHON, a disease characterized by optic nerve dysfunction that leads to painless, subacute loss of central vision.
Asper Biotech recently launched several new reprogenetic tests. The Tartu, Estonia-based firm uses arrayed primer extension to test fetal cells for specific genetic abnormalities.
By Justin PetroneThis story was originally posted Sept. 10
Asper Biotech has introduced array-based prenatal testing for fetuses with increased nuchal translucency but normal karyotype.
Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.
Asper Biotech's Sensorineural Hearing Loss Test, Fujifilm's DMP-5005 Materials Printer, BioForce Nanosciences' ProCleaner Plus
Anagnostics' Hyborg System, Asper Biotech's Congenital Stationary Night Blindness Genetic Test
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.